Quotables
"It is my heart-warmed and world-embracing Christmas hope and aspiration that all of us, the high, the low, the rich, the poor, the admired, the despised, the loved, the hated, the civilized, the savage (every man and brother of us all throughout the whole earth), may eventually be gathered together in a heaven of everlasting rest and peace and bliss, except the inventor of the telephone. "
Mark Twain ; Christmas greetings, 1890
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178531 | Antiviral agents The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention o... | 05/15/2012 |
| 8163707 | 4′-allene-substituted nucleoside derivatives The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or ... | 04/24/2012 |
| 8124584 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring s... | 02/28/2012 |
| 8101643 | Benzimidazole derivatives The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 01/24/2012 |
| 8101567 | Heteroaryl-containing tripeptide HCV serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS... | 01/24/2012 |
| 8030307 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 10/04/2011 |
| RE42375 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 05/17/2011 |
| 7919627 | Processes for the preparation of hydroxylamines The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acce... | 04/05/2011 |
| 7910587 | Quinoxalinyl dipeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 03/22/2011 |
| 7910558 | Bridged macrocyclic compounds and processes for the preparation thereof The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent optionally in the presence of a... | 03/22/2011 |
| 7906513 | Hydrazide-containing hepatitis C serine protease inhibitors The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS... | 03/15/2011 |
| 7842813 | Processes for the preparation of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceuti... | 11/30/2010 |
| 7728148 | Acyclic oximyl hepatitis C protease inhibitors The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A... | 06/01/2010 |
| 7718769 | Tri-peptide hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS... | 05/18/2010 |
| 7718612 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of... | 05/18/2010 |
| 7687459 | Arylalkoxyl hepatitis C virus protease inhibitors The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 03/30/2010 |
| 7662779 | Triazolyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 02/16/2010 |
| 7635683 | Quinoxalinyl tripeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 12/22/2009 |
| 7622452 | C-9 alkenylidine bridged macrolides The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceuti... | 11/24/2009 |
| 7605126 | Acylaminoheteroaryl hepatitis C virus protease inhibitors The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV)... | 10/20/2009 |
| 7601709 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibi... | 10/13/2009 |
| 7589067 | 6, 11-bridged tricyclic macrolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 09/15/2009 |
| 7582605 | Phosphorus-containing hepatitis C serine protease inhibitors The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A proteas... | 09/01/2009 |
| 7566719 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) ... | 07/28/2009 |
| 7563877 | Processes for the preparation of -(2-aminobenzo[]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]ox... | 07/21/2009 |
| 7538225 | Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acce... | 05/26/2009 |
| 7517859 | Spirocyclic bicyclolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 04/14/2009 |
| 7468419 | Cyclosporin derivatives for the treatment of immune disorders The present invention relates to a cyclosporin analog of the following formula (I) or a pro-drug or pharmaceutically acceptable salt thereof: wherein A is of the formula: | 12/23/2008 |
| 7419962 | 3,6-bicyclolides The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical com... | 09/02/2008 |
| 7414030 | 6-11 Bicyclic erythromycin derivatives The present invention discloses compounds of formulaes I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates... | 08/19/2008 |
| 7402568 | Bicyclic 9a-azalide derivatives The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceuti... | 07/22/2008 |
| 7384922 | 6-11 bridged oxime erythromycin derivatives The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 06/10/2008 |
| 7384921 | Polymorphic forms of 6-11 bicyclic ketolide derivatives The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing... | 06/10/2008 |
| 7368452 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) ... | 05/06/2008 |
| 7312201 | Tetracyclic bicyclolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmace... | 12/25/2007 |
| 7291602 | 11,12-lactone bicyclolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmace... | 11/06/2007 |
| 7276487 | 9a, 11-3C-bicyclic 9a-azalide derivatives The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmace... | 10/02/2007 |
| 7273853 | 6-11 bicyclic ketolide derivatives The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmace... | 09/25/2007 |
| 7273851 | Tri-peptide hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (... | 09/25/2007 |
| 7271155 | 9A, 11-2C-bicyclic 9a-azalide derivatives The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to ... | 09/18/2007 |
